不同剂量瑞舒伐他汀对冠心病病人支架植入后血脂水平及心血管事件的影响

Effects of Different Doses of Rosuvastatin on Blood Lipid Level and Cardiovascular Events in Patients with Coronary Heart Disease after Stent Implantation

目的探讨不同剂量瑞舒伐他汀对冠心病(CHD)病人支架植入后血脂水平及心血管事件的影响。方法选取本院心内科2013年8月—2015年8月拟行经皮冠状动脉介入治疗(PCI)的150例CHD病人,随机分为3组,每组50例,分别为低剂量预治疗组(R1组)、中剂量预治疗组(R2组)、高剂量预治疗组(R3组),分别给予5mg、10mg及20mg瑞舒伐他汀之后进行PCI术。记录比较3组病人术前及术后1个月血脂水平、超敏C反应蛋白(hs-CRP)水平及心血管事件发生情况。结果与术前比较,3组术后1个月血脂水平(除高密度脂蛋白胆固醇外)和hs-CRP水平均显著降低(P<0.05),HDL-C显著升高(P<0.05),3组间术后1个月比较,差异有统计学意义(P<0.05)。R3组心血管事件发生率显著低于R1组和R2组,差异有统计学意义(P<0.05)。结论冠心病病人支架植入后应用高剂量瑞舒伐他汀预治疗能显著调节血脂,减少炎症发生,防止术后再狭窄等不良反应。

Objective To investigate the effects of different doses of rosuvastatin on blood lipid level and cardiovascular events in patients with coronary heart disease（CHD）after stent implantation.Methods One hundred and fifty patients with CHD intended to undergo percutaneous coronary intervention（PCI）in our hospital from August 2013 to August 2015 were randomly divided into 3 groups：rosuvastatin low-dose group（group R1,n =50）,medium dose group（group R2,n =50）,high dose group（group R3,n =50）treated with5 mg,10 mg and 20 mg rosuvastatin,respectively.PCI was then performed.Blood lipid levels,high-sensitivity C-reactive protein（hs-CRP）levels and cardiovascular events were observed before and1 month after PCI operation.Results After 1 month of treatment,the levels of serum total cholesterol（TC）,triglyceride（TG）,low density lipoprotein cholesterol（LDL-C）,and hs-CRP decreased while high density lipoprotein cholesterol（HDL-C）level increased in 3 groups（P〈0.05）.The incidence of cardiovascular events in group R3 was significantly lower than that in group R1 and group R2（P〈0.05）.Conclusion High-dose rosuvastatin pretreatment can significantly regulate the blood lipids,reduce the inflammation,and prevent the adverse reactions such as postoperative restenosis after stent implantation in patients with CHD.